Oxygen-Enhanced MRI aims to spot hidden danger in brain tumors
NCT ID NCT05904704
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if a special MRI technique, using extra oxygen, could create maps of low-oxygen areas in brain tumors. Low oxygen can make tumors grow and resist treatment. The goal was to help doctors plan more personalized therapies. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Apr 2023
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients (18 years of age or older) with a known or suspected intracranial tumor * Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf * Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired * Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) magnetic resonance (MR) imaging * Karnofsky performance score \> 60 or Eastern Cooperative Oncology Group (ECOG) \< 3 as assessed by referring clinician * Planning to undergo or previously received therapeutic intervention for the intracranial tumor Exclusion Criteria: * Pregnant or breastfeeding * Contraindication to supplemental oxygen administration, MRI, or intravenous gadolinium based contrast agents. * Claustrophobia * Weight greater than modality maximum capacity * Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \& Science University (OHSU) Department of Radiology guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants) * Sickle cell disease * Unsure of pregnancy status as assessed by Department of Radiology and Advanced Imaging Research Center (AIRC) guidelines * Subjects for whom supplemental oxygen could be harmful such as people with potential for hypoventilation or chronic respiratory insufficiency (end-stage chronic obstructive pulmonary disease \[COPD\], obstructive sleep apnea \[OSA\] on continuous positive airway pressure \[CPAP\]/biphasic positive airway pressure \[Bi-PAP\], etc) * Subjects with a relative contraindication to supplemental oxygen administration will not be provided oxygen but may still participate in the study * Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care) * Poor peripheral intravenous access evaluated by patient history * Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric/social situations which might impact the endpoint of the study or limit compliance with study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Intracranial neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Robot-Assisted brain biopsy study ends early – only 4 patients enrolled
- New imaging agent could sharpen brain tumor detection
- New dye could sharpen PET scans for recurrent brain cancer
- New shorter radiation therapy could tame brain tumors
- No-Mask radiation therapy: a comfortable alternative for head and neck cancer patients?